Nuvectis Pharma, Inc.
NVCT
$6.49
-$0.38-5.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.07M | -20.16M | -19.00M | -19.37M | -21.10M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.40M | 4.93M | 4.86M | 4.94M | 4.91M |
| Change in Net Operating Assets | 4.26M | 3.17M | 1.90M | 805.00K | 1.72M |
| Cash from Operations | -12.41M | -12.06M | -12.25M | -13.63M | -14.47M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 22.87M | 23.99M | 12.04M | 8.98M | 8.62M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.79M | -1.52M | -382.00K | -242.00K | -629.00K |
| Cash from Financing | 21.09M | 22.46M | 11.65M | 8.74M | 7.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.68M | 10.40M | -593.00K | -4.89M | -6.48M |